Literature DB >> 19869473

FACTORS INVOLVED IN THE PRODUCTION OF IMMUNITY WITH PNEUMOCOCCUS VACCINE : I. ACTIVE AND PASSIVE IMMUNITY DURING THE FIRST SEVEN DAYS AFTER INJECTION OF ANTIGEN.

A L Barach1.   

Abstract

1. The antigenic function of a pneumococcus vaccine made from the intact cell was compared with that derived fron a watery extract of the cell free from formed elements. In each instance, the immunity produced was dependent upon type-specific protective substance and not upon the elaboration of the common protein antibody. 2. The vaccine made from the intact cell resulted in both active and passive immunity which began on the 3rd day, increased markedly to the 5th, and remained approximately stationery to the 7th day. In the case of the Berkefeld filtrate of the shaken bacteria and the filtrate of the broth culture, the immunity began on the 4th day, increased to the 5th, and remained approximately stationery to the 7th day. The immunity produced by Pneumococcus Type I vaccine is greater than that produced by Type II. On the 3rd day, mice vaccinated with Type I vaccine resisted 100,000 minimal lethal doses, whereas mice immunized with Type II resisted 10,000 minimal lethal doses. On the 5th day, a larger percentage of mice survived these doses than on the 3rd day. 3. Certain factors related to the preparation and dosage of the vaccine are discussed. 4. As far as the time interval and the degree of immunity produced are concerned, these results suggest the possibility of employing pneumococcus vaccine in suitable doses in the treatment of lobar pneumonia. That an earlier activity of the immunity mechanism could actually be initiated in a patient with lobar pneumonia has still to be demonstrated.

Entities:  

Year:  1928        PMID: 19869473      PMCID: PMC2131460          DOI: 10.1084/jem.48.1.83

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  IMMUNOLOGICAL RELATIONSHIPS OF CELL CONSTITUENTS OF PNEUMOCOCCUS : SECOND PAPER.

Authors:  O T Avery; M Heidelberger
Journal:  J Exp Med       Date:  1925-08-31       Impact factor: 14.307

2.  STUDIES ON PNEUMOCOCCUS IMMUNITY : II. ACTIVE IMMUNIZATION OF MONKEYS AGAINST PNEUMOCOCCUS TYPES II, III, AND IV PNEUMONIA WITH THE HOMOLOGOUS PNEUMOCOCCUS VACCINE.

Authors:  R L Cecil; G I Steffen
Journal:  J Exp Med       Date:  1923-07-31       Impact factor: 14.307

3.  THE PRESENCE OF PROTECTIVE SUBSTANCES IN HUMAN SERUM DURING LOBAR PNEUMONIA.

Authors:  A R Dochez
Journal:  J Exp Med       Date:  1912-11-01       Impact factor: 14.307

4.  THE ELABORATION OF SPECIFIC SOLUBLE SUBSTANCE BY PNEUMOCOCCUS DURING GROWTH.

Authors:  A R Dochez; O T Avery
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

5.  THE PRODUCTION OF ANTIPNEUMOCOCCIC SERUM.

Authors:  R Cole; H F Moore
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

6.  STUDIES ON IMMUNITY TO PNEUMOCOCCUS MUCOSUS (TYPE III) : III. INCREASED RESISTANCE TO TYPE III INFECTION INDUCED IN RABBITS BY IMMUNIZATION WITH R AND S FORMS OF PNEUMOCOCCUS.

Authors:  W S Tillett
Journal:  J Exp Med       Date:  1927-07-31       Impact factor: 14.307

7.  STUDIES ON PNEUMOCOCCUS INFECTION IN ANIMALS : SECOND PAPER: ACTION OF IMMUNE SERA ON PNEUMOCOCCUS INFECTION.

Authors:  A B Wadsworth
Journal:  J Exp Med       Date:  1912-07-01       Impact factor: 14.307

  7 in total
  3 in total

1.  THE EFFECT OF THE ROUTE OF IMMUNIZATION ON THE IMMUNITY RESPONSE TO PNEUMOCOCCUS TYPE I.

Authors:  E G Stillman
Journal:  J Exp Med       Date:  1930-04-30       Impact factor: 14.307

Review 2.  The remarkable history of pneumococcal vaccination: an ongoing challenge.

Authors:  Daniel M Musher; Ronald Anderson; Charles Feldman
Journal:  Pneumonia (Nathan)       Date:  2022-09-25

3.  FACTORS INVOLVED IN THE PRODUCTION OF IMMUNITY WITH PNEUMOCOCCUS VACCINE : II. INDUCTION OF ACTIVE IMMUNITY DURING THE COURSE OF LOBAR PNEUMONIA.

Authors:  A L Barach
Journal:  J Exp Med       Date:  1931-03-31       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.